
BioVersys and Shionogi agree to develop ansamycin leads
BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads from the former’s BV500 programme into clinical candidates. BioVersys is eligible for upfront and near-term research …